Dr. David Y. Liu Ph.D.Chief Scientific Officer and Head of R&D
Total compensation: $403,000
Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing peptide-based chemical entities to address various unmet medical needs. It primarily focuses on developing oral peptide drugs. The company's lead product candidates include PTG-100, an oral alpha-4-beta-7 integrin-specific antagonist that is in phase II clinical trial for the treatment of inflammatory bowel disease (IBD); and PTG-200, an interleukin-23 receptor specific antagonist, which is under pre-clinical development stage for the treatment of IBD. It is also developing PTG-300, an injectable hepcidin mimetic peptide that is in pre-clinical development stage to treat iron overload disorders, such as b-Thalassemia, hereditary hemochromatosis, and sickle cell disease. The company was founded in 2006 and is headquartered in Milpitas, California.
- Protagonist Therapeutics, Inc., 7707 Gateway Boulevard, Milpitas 94560, United States
- 510 474 0170